INTRODUCTION
The expression of CARs in T lymphocytes to redirect their antigen specificity has significantly expanded the clinical application of adoptive T-cell immunotherapies against a variety of human malignancies (1, 2) . CAR molecules are chimeric proteins in which a single chain antibody binding site is fused with the signaling domain CD3ζ that activates T lymphocytes upon binding to the tumor antigen (3) . However, in this form CAR molecules do not provide adequate costimulation to T cells (1, 4, 5) . To overcome this limitation, CARs can be expressed by CTLs whose native receptors are specific for virus latency proteins such as those derived from the EBV-CTLs (6, 7) . These virus-specific CTLs can receive physiologic costimulation from professional antigen presenting cells processing latent viral antigens and kill tumor cells through their CAR (6, 7) . While this approach can produce complete and sustained antitumor responses, for example in some patients with neuroblastoma, in most recipients CAR-engrafted EBV-CTLs have limited in vivo survival and fail to consistently eradicate disease (8, 9) . It is likely that the combination of host/tumor associated inhibitory factors and insufficient in vivo immunostimulation limit the expansion and persistence of these cells (10) .
Regulatory T cells (Tregs) play a significant role in impairing the antitumor effects of tumor-specific CTLs (11) . Tregs are frequently increased in the peripheral blood and in tumor biopsies of cancer patients (12) (13) (14) (15) (16) (17) , and their presence often correlates with poor clinical outcome (15) . Thus, the development of strategies aimed at eliminating Tregs or at selectively favoring the expansion of antitumor CTLs may significantly contribute in enhancing the engraftment and antitumor effects of adoptively transferred CTLs. To date, most efforts to increase in vivo immunostimulation of adoptively transferred T cells have focused on administration of IL-2 (18) . Although this cytokine is a potent T-cell growth factor, it is not selective for effector T-cell subsets, and can also enhance the growth and inhibitory activity of Tregs (19) .
One means by which T lymphocytes can be selectively expanded is by using IL-7, a γ-chain cytokine that promotes homeostatic expansion of naïve and memory T cells but has no activity on Tregs, which lack the IL-7Rα (the private chain of the IL-7 receptor) (20) (21) (22) (23) . Administration of recombinant IL-7 was well tolerated in early phase clinical trials, and expanded naive and central-memory T-cell subsets but not Tregs (20, 5 expansion of adoptively transferred CAR-redirected CTLs as this is an effector-memory T-cell subset that, like Tregs, also lacks IL-7Rα (24) .
Here we developed models in vitro and in vivo to demonstrate that human Tregs clearly inhibit the antitumor effects of CAR-redirected EBV-CTLs. We also show that selective modulation of the IL-7 cytokine-cytokine receptor axis in CAR-engrafted EBV-CTLs augments their antitumor effects in vivo in the presence of Tregs. This strategy should safely enhance the persistence and survival of adoptively transferred CAR-redirected virus-specific CTLs in cancer patients.
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MATERIALS AND METHODS
Plasmid construction, retrovirus production and tumor cell lines. The full-length human IL-7Rα linked through the 2A(TAV) sequence to the CAR-GD2 encoding the CD28 endodomain (25) was cloned into the SFG retroviral vector to generate the bicistronic vector SFG.IL-7Rα.CAR-GD2. The retroviral vectors encoding eGFP and Firefly Luciferase (FFLuc) were previously described (26) . Retroviral supernatant was prepared using transient transfection of 293T cells (26) . The neuroblastoma cell line CHLA-255(27) (kindly provided by Dr Leonid Metelitsa) was derived from a patient, and we verified that this line retains the surface expression of the target antigen GD2.
Generation and transduction of EBV-CTLs. EBV-transformed lymphoblastoid cells
(LCLs) and EBV-CTLs were prepared using peripheral blood mononuclear cells (PBMCs), obtained from healthy donors as previously described (28) . EBV-CTLs were transduced with retroviral supernatant after three stimulations with autologous LCLs, as previously described (8) , and then maintained in culture by weekly stimulation with LCLs and recombinant IL-2 (50 IU/ml) or IL-7 (2.5 ng/ml) (PeproTech; Rocky Hill, NJ).
Expansion of Tregs.
To obtain significant numbers of cells for the in vitro and in vivo experiments, Tregs were isolated and expanded as previously described (29) . Briefly,
CD25
bright T cells were purified from PBMCs by positive selection using immunomagnetic selection in the presence of non-saturating concentrations (2 μl/1 x 10 7 PBMCs) of anti-human CD25 magnetic beads (Miltenyi Biotech, Germany). On day 0, the purified CD25 + T cells were activated in 24-well plates coated with OKT3 (1 µg/mL) and anti-CD28 antibody (BD Pharmingen, Franklin Lakes, New Jersey) (1 µg/mL) in RPMI-1640 in the presence of rapamycin (Sigma, St Louis, MO) at a final concentration of 100 nM. On days 7 and 14, cells were restimulated with OKT3/CD28 antibodies, irradiated feeder cells, rapamycin and IL-2 (50 IU/mL) in small bioreactors (G-REX) (29) .
At the end of the 3 week culture (day 21), cells were used for in vitro and in vivo experiments. The cell fraction obtained from buffy coats after the selection of CD25 bright T cells was further enriched for CD4 + cells which were then used as negative control in parallel culture experiments in which we evaluated the immunosuppressive activity of
Tregs (29, 30) .
Research. and FoxP3 from eBioscience Inc (San Diego, CA, USA). CAR-GD2 expression by transduced EBV-CTLs was detected using the specific anti-idiotype antibody 1A7, followed by staining with the secondary antibody RAM-IgG1-PE (Becton Dickinson) (8) .
STAT5 phosphorylation in Tregs and EBV-CTLs was assessed after cytokine stimulation for 15 minutes using the anti-phospho-STAT5 (Y694) mAb-Alexa Fluor 647 Conjugate (BD Phosflow Reagents, San Jose, CA). Cells were analyzed using a BD FACScalibur system equipped with the filter set for quadruple fluorescence signals and the CellQuest software (BD Biosciences). For each sample, we analyzed a minimum of 10,000 events.
Carboxyfluorescein diacetate succinimidyl ester (CFSE)-based assays.
Proliferation of Tregs or EBV-CTLs or activated PBMC was assessed by CFSE dilution.
Briefly, EBV-CTLs were labeled with 1.5 μM CFSE (Invitrogen) and activated with LCLs (ratio 4:1) with or without IL-2 (12.5 IU/ml) or IL-7 (10 ng/ml). 
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RESULTS
Functional IL-7Rα and CAR-GD2 can be coexpressed in EBV-CTLs. To restore the responsiveness to IL-7 and to redirect the antigen specificity of EBV-CTLs against neuroblastoma, we generated a bicistronic γ-retroviral vector encoding the IL-7Rα and a GD2-specific CAR linked through a 2A (TAV) sequence (SFG.IL-7Rα.2A.CAR-GD2) (Fig. 1A) . EBV-CTLs established from 5 healthy EBV-seropositive donors were transduced with the vector, and the expression of both IL-7Rα and CAR-GD2 was measured by FACS analysis. As shown in Fig. 1B , both CAR-GD2 and IL-7Rα were stably expressed (64% ± 3% and 34% ± 9%, respectively) in transduced EBV-CTLs, while the expression of the native IL-7Rα on control cells remained negligible (4% ± 1%).
To evaluate the functionality of the transgenic IL-7Rα, we measured the phosphorylation of STAT5 in response to either IL-2 or IL-7. In the absence of cytokines, control and IL-7Rα.CAR-GD2 + EBV-CTLs showed negligible phosphorylation of STAT5 (3% ± 2% and 8% ± 4%, respectively). In IL-7Rα.CAR-GD2 + EBV-CTLs, near equal STAT5 phosphorylation of Tyr-694 was detected in response to IL-2 (49% ± 7%) or IL-7 (38% ± 6%, respectively) (p= NS). By contrast, in control cells, STAT5 was phosphorylated in response to IL-2 (63% ± 8%) but not to IL-7 (6% ± 5%) (p < 0.05) (Fig. 1C) . The levels of IL-7Rα-dependent STAT5 phosphorylation in IL-7Rα.CAR-GD2 + EBV-CTLs exposed to IL-7 were very similar to the amount observed in T lymphocytes physiologically expressing the IL-7Rα and exposed to IL-7 ( Supplementary Fig. 1A ).The functionality of the transgenic IL-7Rα was further supported by progressive selection of transgenic cells if cultures were supplemented with IL-7. As illustrated in Fig. 1D (and Supplementary Fig. 1B ), when IL-7Rα.CAR-GD2 + CTLs were stimulated weekly with autologous LCLs and IL-7, the expression of both IL-7Rα and CAR-GD2 progressively increased between the third and sixth antigen-specific stimulation (from 34% ± 9% to 66% ± 5% for IL-7Rα, and from 64% ± 3% to 80% ± 7% for CAR-GD2). By contrast, when CTLs were expanded in the presence of IL-2, no enrichment of either transgenes was observed, since this cytokine equally supports the ex vivo growth of transduced and non transduced CTLs (data not shown).
The enrichment of transgenic T cells following exposure to IL-7 was a consequence of the proliferation of IL-7Rα.CAR-GD2 + EBV-CTLs. As illustrated in Fig. 2A with LCLs (ratio 4:1) in the presence of IL-2 (proliferation: 68% ± 6% and 68% ± 4%, respectively). By contrast, in the presence of IL-7, IL-7Rα.CAR-GD2 + but not control EBV-CTLs had significantly greater proliferation: 63% ± 3% vs. 14% ± 1%, respectively (p<0.001). The number of EBV-CTLs proliferating in response to EBV-LCLs and IL-7
was generally higher than expected based on the ectopic expression of IL-7Rα. This higher level is likely a consequence of the physiological production of IL-2 by EBV-CTLs in response to their cognate EBV antigens (EBV-LCLs) (Supplementary Fig. 2) . Finally, exposure of IL-7Rα.CAR-GD2 + EBV-CTLs to IL-7 did not affect their antitumor properties. As shown in Fig. 2B , when EBV-CTLs were cultured with CHLA-255 cells, only IL-7Rα.CAR-GD2 + cells controlled tumor growth in the presence of either IL-2 or IL-7 (6% ± 1% and 4% ± 1%, respectively), while tumor cells outgrew in cultures containing control EBV-CTLs irrespective of the cytokine added (43% ± 5% and 57% ± 12%, respectively) (p<0.001).
Ex vivo expanded Tregs do not respond to IL-7.
We used ex vivo expanded (Fig. 3B) . As a consequence, STAT5 was only phosphorylated in these Tregs in response to IL-2 (MFI = 75 ± 9) (p<0.001) and not in response to IL-7 (MFI = 23 ± 3) (Fig. 3C) . Finally, a CFSE-based dilution assay
showed that Tregs only proliferated after polyclonal activation in the presence of IL-2
and not on exposure to IL-7 (MFI 1439 ± 207 vs 445 ± 68, respectively; p<0.001) (Fig.   3D ).
Research. While IL-7 shares several functions with IL-2, it also has effects on specific T-cell subsets that depend on their expression of the private IL-7Rα subunit (23) . Our experiments demonstrate both in vitro and in vivo that IL-7 can nonetheless support the survival, expansion and effector function of CAR-redirected EBV-CTLs if these cells are engineered to re-express the IL-7Rα, and that it can thereby overcome the inhibitory effects of Tregs. Our approach has significant advantages over the use of IL-2 or cytotoxic drugs to eliminate Tregs in a non-selective manner (40) since it may promote the long-term persistence of CAR-redirected EBV-CTLs both in steady state conditions and in a lymphopenic environment (23) . In addition, the administration of recombinant IL-7 unlike recombinant IL-2 appears to be well tolerated even at high doses (20, 21, 41) . One potential concern associated with any genetic manipulation of T cells is that the cells will undergo malignant transformation, or grow in an antigen independent manner. This concern is particularly prominent when the genetic manipulation modifies a growth factor receptor or other portions of a signaling pathway. However, the experience of our own and other groups has been that the genetic manipulation of differentiated T cells to express cytokines or cytokine receptors does not affect the antigen-specificity of these cells and does not elicit uncontrolled proliferation (24, 37, 43) . These results were confirmed in the current study even if we can not completely exclude the possibility of secondary paracrine effects due to the ectopic expression of IL-7Rα. If such a concern remains, however, incorporation of suicide or safety switches within the cells may provide a further level of reassurance (37, 44) .
Our study suggests that restoring the responsiveness to IL-7 of virus-specific CTLs redirected with a CAR is a strategy that may allow enhanced T-effector cells without concomitant inhibition by Treg and may thereby further improve the clinical outcome of a promising therapeutic approach. Panel B illustrates the mean ± SD of photons for 8 mice/group in two independent experiments. * p<0.05.
Research. 
